It was reported that a patient underwent a cardiac ablation procedure with a thermocool® smart touch® sf bi-directional navigation catheter and the patient experienced pericardial effusion requiring a pericardiocentesis.After pulmonary vein isolation (pvi), while creating cavotricuspid ishmus (cti) line, blood pressure decrease was confirmed.Pericardial effusion was confirmed by echocardiography and pericardial drainage was performed.Blood pressure was stabilized by pericardial drainage.Atrial septal puncture was performed with rf needle.Ablation was performed before pericardial effusion or tamponade was confirmed.Steam pop was not confirmed.No abnormalities observed prior to or during use of the product.Additional information was later received indicating the patient has fully recovered.No error messages observed on biosense webster equipment during the procedure.The physician's opinion on the adverse event is that it was possibly procedure related but could not determined.
|
Device investigation details: available information indicates that the device is not available for return, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A manufacturing record evaluation was performed for the finished device number lot 31215020l and no internal action related to the complaint was found during the review.As part of our company quality system process, all devices are manufactured, inspected, and distributed to approved specifications.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.E1.Initial reporter phone: (b)(6).If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|